Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D UPDEGROVE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1518933308
CMS profile
205052
Location
CORSICANA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$27.77

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $27.77 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $27.77 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D UPDEGROVE

NPI 1518933308 · CMS profile ID 205052

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CORSICANA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518933308?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D UPDEGROVE, NPI 1518933308, CMS profile ID 205052. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518933308?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN D UPDEGROVE, NPI 1518933308, CMS profile ID 205052. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518933308?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN D UPDEGROVE, NPI 1518933308, CMS profile ID 205052, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1518933308?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $27.77 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $27.7710/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 916860513 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $27.77 1
PY2023 $65.25 1
PY2024 $23.03 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $314,315.48 99
PY2024 Principal investigator $273,588.23 61
PY2023 Principal investigator $155,995.83 32
PY2022 Principal investigator $47,617.22 8
PY2021 Principal investigator $19,079.96 12
PY2020 Principal investigator $37,064.71 15
PY2019 Principal investigator $38,041.05 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

99 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $1,855.10 12/22/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131633
Principal investigator 1 Genentech, Inc. $150.00 12/11/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591157
Principal investigator 1 Genentech, Inc. $888.37 12/11/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591168
Principal investigator 1 Genentech, Inc. $550.00 12/11/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591173
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.90 12/11/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044332
Principal investigator 1 Genentech, Inc. $218.00 12/09/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591152
Principal investigator 1 Genentech, Inc. $210.00 12/09/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591161
Principal investigator 1 SANOFI US SERVICES INC. $2,300.00 12/08/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131629
Principal investigator 1 Genentech, Inc. $11,137.00 12/01/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591165
Principal investigator 1 Genentech, Inc. $1,818.00 11/21/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591136
Principal investigator 1 Genentech, Inc. $400.00 11/18/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591132
Principal investigator 1 Genentech, Inc. $218.00 11/18/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591140
Principal investigator 1 Genentech, Inc. $218.00 11/06/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591144
Principal investigator 1 Genentech, Inc. $20,578.00 11/03/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591147
Principal investigator 1 Verona Pharma, Inc. $326.82 11/03/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891755
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 10/29/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044334
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.90 10/29/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044336
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,461.90 10/29/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044338
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.90 10/29/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044400
Principal investigator 1 Genentech, Inc. $218.00 10/21/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591106
Principal investigator 1 Genentech, Inc. $400.00 10/21/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591123
Principal investigator 1 Genentech, Inc. $550.00 10/21/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591128
Principal investigator 1 Genentech, Inc. $550.00 10/16/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591110
Principal investigator 1 SANOFI US SERVICES INC. $13,450.00 10/14/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226131622
Principal investigator 1 SANOFI US SERVICES INC. $4,081.70 10/14/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131625
Principal investigator 1 Verona Pharma, Inc. $8,793.01 10/10/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891753
Principal investigator 1 Genentech, Inc. $950.00 10/07/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591116
Principal investigator 1 Genentech, Inc. $1,818.00 10/02/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591120
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.90 09/25/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044340
Principal investigator 1 Verona Pharma, Inc. $6,698.81 09/17/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891641
Principal investigator 1 SANOFI US SERVICES INC. $1,855.10 09/15/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131620
Principal investigator 1 GlaxoSmithKline, LLC. $2,250.00 09/05/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192186431
Principal investigator 1 GlaxoSmithKline, LLC. $9,500.00 09/05/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192186435
Principal investigator 1 Genentech, Inc. $1,500.00 08/27/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591090
Principal investigator 1 Genentech, Inc. $12,856.00 08/19/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591094
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,461.90 08/19/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044342
Principal investigator 1 SANOFI US SERVICES INC. $2,750.60 08/18/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131616
Principal investigator 1 Genentech, Inc. $500.00 08/07/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591102
Principal investigator 1 Genentech, Inc. $450.00 08/05/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591098
Principal investigator 1 Verona Pharma, Inc. $9,000.00 07/25/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891625
Principal investigator 1 Verona Pharma, Inc. $1,500.00 07/25/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891627
Principal investigator 1 Genentech, Inc. $7,272.00 07/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591085
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.90 07/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044344
Principal investigator 1 SANOFI US SERVICES INC. $700.00 07/21/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131604
Principal investigator 1 SANOFI US SERVICES INC. $1,855.10 07/14/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131610
Principal investigator 1 Genentech, Inc. $650.00 07/10/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591082
Principal investigator 1 Genentech, Inc. $650.00 06/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591065
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,397.80 06/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044346
Principal investigator 1 Genentech, Inc. $13,919.00 06/17/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591026
Principal investigator 1 Genentech, Inc. $946.00 05/28/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591042
Principal investigator 1 SANOFI US SERVICES INC. $10,411.08 05/27/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131601
Principal investigator 1 Genentech, Inc. $700.00 05/21/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591053
Principal investigator 1 Genentech, Inc. $17,378.00 05/20/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591030
Principal investigator 1 Genentech, Inc. $6,230.00 05/16/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591056
Principal investigator 1 SANOFI US SERVICES INC. $1,029.00 05/12/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131598
Principal investigator 1 Genentech, Inc. $5,210.00 05/07/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591073
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,000.00 05/07/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244044380
Principal investigator 1 SANOFI US SERVICES INC. $6,113.38 05/05/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131592
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,932.00 04/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044348
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $34.48 04/24/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045576
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $246.40 04/24/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045578
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3.45 04/24/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045580
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3.00 04/24/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045582
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 04/21/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131595
Principal investigator 1 Genentech, Inc. $3,636.00 04/15/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591069
Principal investigator 1 SANOFI US SERVICES INC. $2,861.46 04/07/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131589
Principal investigator 1 Genentech, Inc. $149.37 04/03/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591045
Principal investigator 1 SANOFI US SERVICES INC. $11,500.00 04/02/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131583
Principal investigator 1 Genentech, Inc. $7,272.00 04/01/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591035
Principal investigator 1 Genentech, Inc. $550.00 04/01/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591038
Principal investigator 1 Genentech, Inc. $400.00 04/01/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591050
Principal investigator 1 Genentech, Inc. $889.00 04/01/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591061
Principal investigator 1 Genentech, Inc. $450.00 04/01/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591078
Principal investigator 1 Genentech, Inc. $387.00 03/25/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591014
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,253.00 03/20/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044350
Principal investigator 1 Genentech, Inc. $3,126.00 03/19/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591018
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $215.88 03/18/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244044460
Principal investigator 1 SANOFI US SERVICES INC. $1,750.00 03/17/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131575
Principal investigator 1 GlaxoSmithKline, LLC. $627.34 03/12/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192186424
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,736.30 02/27/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044352
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044458
Principal investigator 1 Genentech, Inc. $6,252.00 02/19/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591000
Principal investigator 1 Genentech, Inc. $15,032.00 02/18/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590962
Principal investigator 1 SANOFI US SERVICES INC. $2,840.46 02/18/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131578
Principal investigator 1 Genentech, Inc. $150.00 02/11/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590966
Principal investigator 1 Genentech, Inc. $889.00 02/11/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590979
Principal investigator 1 Genentech, Inc. $889.00 02/06/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590984
Principal investigator 1 Genentech, Inc. $4,545.00 02/06/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590988
Principal investigator 1 Genentech, Inc. $149.37 02/06/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591004
Principal investigator 1 Genentech, Inc. $300.00 02/04/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590958
Principal investigator 1 Genentech, Inc. $550.00 02/04/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590971
Principal investigator 1 Genentech, Inc. $1,000.00 02/04/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590992
Principal investigator 1 Genentech, Inc. $450.00 02/04/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211590996
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $571.90 01/30/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044354
Principal investigator 1 Genentech, Inc. $4,914.00 01/24/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211590975
Principal investigator 1 SANOFI US SERVICES INC. $4,100.00 01/21/2025 Non-covered Recipient Entity
Corsicana Medical Research PLLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131569
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,121.30 01/16/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244044356
Principal investigator 1 Genentech, Inc. $3,126.00 01/08/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211591008
Principal investigator 1 Genentech, Inc. $8,425.00 01/07/2025 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211591022